Sana Biotechnology, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SANA research report →
Companywww.sana.com
Sana Biotechnology, Inc. , a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.
- CEO
- Steven D. Harr
- IPO
- 2021
- Employees
- 194
- HQ
- Seattle, WA, US
Price Chart
Valuation
- Market Cap
- $865.49M
- P/E
- -3.56
- P/S
- 0.00
- P/B
- 7.22
- EV/EBITDA
- -4.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -161.87%
- ROIC
- -78.61%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-244,166,000 · 8.47%
- EPS
- $-0.96 · 17.24%
- Op Income
- $-190,958,000
- FCF YoY
- 43.58%
Performance & Tape
- 52W High
- $6.55
- 52W Low
- $1.81
- 50D MA
- $3.25
- 200D MA
- $3.88
- Beta
- 2.18
- Avg Volume
- 3.42M
Get TickerSpark's AI analysis on SANA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 6, 26 | Bishop Hans Edgar | other | 7,763 |
| Mar 24, 26 | PATEL DHAVALKUMAR DHIRAJLAL | other | 0 |
| Mar 24, 26 | PATEL DHAVALKUMAR DHIRAJLAL | other | 506,250 |
| Mar 24, 26 | PATEL DHAVALKUMAR DHIRAJLAL | other | 112,500 |
| Mar 24, 26 | PATEL DHAVALKUMAR DHIRAJLAL | other | 375,000 |
| Mar 24, 26 | PATEL DHAVALKUMAR DHIRAJLAL | other | 515,000 |
| Mar 7, 26 | Harr Steve | other | 50,000 |
| Mar 9, 26 | Harr Steve | other | 11,526 |
| Mar 9, 26 | Harr Steve | other | 12,819 |
| Mar 6, 26 | Harr Steve | other | 41,666 |
Our SANA Coverage
We haven't published any research on SANA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SANA Report →